Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Nona Biosciences Announces Attendance at PEGS Europe 2022 2022-11-15 15:57
HARBOUR BIOMED LAUNCHES NONA BIOSCIENCES' "IDEAS TO IND" PRECLINICAL SOLUTIONS BUSINESS TO ACCELERATE GLOBAL BIOTHERAPEUTIC INNOVATION 2022-11-15 12:19
Harbour BioMed Enters into a License and Collaboration Agreement with Moderna 2022-11-11 09:03
Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody in the United States 2022-10-20 16:20
Harbour BioMed Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting 2022-10-13 19:05
Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti-TSLP Fully Human Monoclonal Antibody 2022-09-27 21:40
Harbour BioMed to Announce 2022 Interim Results on August 31, 2022 2022-08-09 15:00
PNAS Published Preclinical Results of Harbour BioMed's Next-Generation Fully Human Heavy-chain Antibody Porustobart 2022-08-08 17:43
Harbour BioMed Announces IND Clearance for B7H4x4-1BB Bispecific Antibody by the U.S. Food and Drug Administration 2022-06-27 19:04
Harbour BioMed Announces IND Approval for B7H4x4-1BB Bispecific Antibody 2022-06-08 18:11
Harbour BioMed Reports the Latest Progress of Next-Generation Fully Human Heavy-chain Antibody HBM4003 with Unique Treg Depletion Mechanism 2022-06-01 21:24
Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody 2022-05-25 17:42
Harbour BioMed to Present the Latest Progress of Next-Generation Anti-CTLA-4 Antibody HBM4003 at 2022 ASCO Annual Meeting 2022-05-10 16:54
Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board 2022-05-06 08:00
Harbour BioMed Appoints Dr. Humphrey Gardner as Chief Medical Officer 2022-04-14 08:46
Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022 2022-04-07 09:09
Harbour BioMed Announces Poster Presentation on the Novel Bispecific Antibody PD-L1xCD40 at Upcoming American Association for Cancer Research (AACR) Annual Meeting 2022-04-06 15:04
Harbour BioMed Reports Full Year 2021 Financial Results: Empower Value Creation with Global Innovation Capabilities 2022-03-25 10:22
Harbour BioMed Announces IND Approval for Next-Gen Anti-TSLP Fully Human Monoclonal Antibody 2022-02-21 20:29
Harbour BioMed Announces Dosing of First Patient in Combination Therapy Phase Ib/IIa Trial of Next-Generation Anti-CTLA-4 Antibody 2022-01-24 15:39
1 2 3